trustworthy, and credible health information and tools for patients from DG Academy of Family Physicians., patient information, patient education, health information, medical, advice
Saturday, 6 October 2012
Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis
CONTEXT Concerns exist regarding the potential development of malignancies in patients with rheumatoid arthritis (RA) who are receiving biologic response modifiers (BRMs). OBJECTIVETo assess the risk of malignancy in patients with RA enrolled in randomized controlled trials (RCTs) of BRMs. DATA SOURCESElectronic databases, conference proceedings, and websites of regulatory agencies were searched for RCTs evaluating abatacept, adalimumab, anakinra, certolizumab, etanercept, golimumab, infliximab, rituximab, and tocilizumab in RA from inception through July 9, 2012. STUDY SELECTIONIndependent selection of studies included RCTs that compared the safety of any BRMs used in RA patients with placebo and/or any traditional disease-modifying antirheumatic drugs with a minimum of 24 weeks of follow-up. DATA EXTRACTIONIndependent reviewers selected studies and extracted data on quality and outcomes. Pooled estimates and 95% confidence intervals were calculated for each BRM. RESULTSSixty-three RCTs with 29,423 patients were analyzed. No statistically significant increased risk of developing malignancy was observed. Of the 29,423 patients, 211 developed a malignancy during the trial (118 solid tumors, 48 skin cancers, 14 lymphomas, 5 hematologic nonlymphomas, and 26 not specified). The incidence rate for any malignancy during the first year of therapy was very low in the BRM plus methotrexate group (0.77%; 95% CI, 0.65%-0.92%), the BRM monotherapy group (0.64%; 95% CI, 0.42%-0.95%), and the controls (0.66%; 95% CI, 0.52%-0.84%). Anakinra plus methotrexate showed lower odds compared with methotrexate alone (Peto odds ratio, 0.11; 95% CI, 0.03-0.45). No statistically significant risk was observed for specific cancer sites, although the Peto odds ratio for lymphoma was 2.1 (95% CI, 0.55-8.4) in patients receiving tumor necrosis factor inhibitors compared with controls. CONCLUSIONThe use of BRMs among patients with RA included in RCTs of at least 6 months' duration was not significantly associated with an increased risk of malignancy compared with other disease-modifying antirheumatic drugs or with placebo.
Subscribe to:
Post Comments (Atom)
30 Days Popular Posts
-
DENTISTS Dentists, Dental Clinics in Gurgaon, Dentists, Surgeons, Clinics Dr. Monica Kishore, BDS, M.Med.Sc(U...
-
U.S. News surveyed nearly 10,000 specialists and sifted through data for approximately 5,000 hospitals to rank the best...
All Time Popular Posts
-
PHYSIOTHERAPY Dr. Geeta Tekchand, Sushant Lok-I : 9312624490 Dr. Manish Pahuja : 9811576421 Dr. Manoj Sharma : 987...
-
By Tony Monterastelli, WomensHappiness.com Staff Writer Are you frustrated by guys' over-reliance on tex...
-
QUESTION from the WomensHappiness Forum: Any thoughts on how to deal with a player? I feel really stupid be...
-
Q: Can you explain to me what the Madonna/Whore thing is in men? How would you deal with a man with this co...
-
GYNAECOLOGY Gynaecologists and Maternity Homes & Clinics in Gurgaon Gurgaon gynecologist obstetricians obstetri...
-
Question: How might a woman be able to have casual sex and still be regarded with a high degree of respect,...
-
ENT SPECIALISTS gurgaon ENT doctors in gurgaon, gurgaon ent clinics in gurgaon, Ear Nose Throat, Clinic, Doctor, Specialist ...
-
DG Event .In 09891478560, 09891478183 projector on rent in gurgaon bhiwdi delhi Ncr http://www.dgevent.in/av-lcd-projector-rent-gurgao...
-
DENTISTS Dentists, Dental Clinics in Gurgaon, Dentists, Surgeons, Clinics Dr. Monica Kishore, BDS, M.Med.Sc(U...
-
Address : jamshedpur - 831018 jharkhand
No comments:
Post a Comment